Radiopharmaceutical Business Division of CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. from Kim Jong-woo and others, in a reverse merger transaction for approximately KRW 210 billion.
November 23, 2020
Share
Radiopharmaceutical Business Division of CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. (XKON:A176750) from Kim Jong-woo and others, in a reverse merger transaction for approximately KRW 210 billion on November 24, 2020. As part of the transaction, 18.2 million new shares of DuChemBIO to be issued to the shareholders of Care Camp. and the split-merger ratio is 1:9.2. Post the transaction, Duchem Bio Co., Ltd. will remain as a surviving company, and Care Camp will continue to exist as a business division. Upon completion of the merger, the largest shareholder of the surviving company will be Geoyoung Co., Ltd., and the expected share of the largest shareholder is 51.83%, and Geoyoung Co., Ltd. plans to jointly manage the surviving company by signing a shareholder agreement with Kim Jong-woo, the second largest shareholder. Upon completion of the merger, the estimated combined stake of Geoyoung and Jongwoo Kim is 63.07%. The Board of Directors of DuChemBIO resolved the transaction. The meeting of DuChemBIO Co.,Ltd., shareholders for the approval of the transaction is scheduled to be held on June 22, 2021. As of May 28, 2021, the meeting of DuChemBIO Co.,Ltd., shareholders is to be held on July 26, 2021, whereas the listing of new share is expected to occur on August 31, 2021 after the correction from August 2, 2021. On August 6, 2021, merger schedule period of exercise of stock appraisal right end date got correct to August 17, 2021. Period of exercise of stock appraisal right changed to July 26, 2021~August 17, 2021. The merger is expected to be effective on June 15, 2021. As of April 23, 2021, the transaction is expected to be completed by July 31, 2021. As of May 28, 2021, the transaction is expected to complete on August 31, 2021.
DuChemBio Co Ltd is a Korea-based company principally engaged in the manufacture and sale of radiopharmaceuticals. The Company is engaged in the manufacture and sale of diagnostic radiopharmaceuticals such as radiopharmaceuticals for the diagnosis of Parkinson's disease, radiopharmaceuticals for the diagnosis of Alzheimer's disease, and radiopharmaceuticals for the diagnosis of brain tumors. In addition, the Company is engaged in the sale of computed tomography (CT) contrast agents and other products.
Radiopharmaceutical Business Division of CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. from Kim Jong-woo and others, in a reverse merger transaction for approximately KRW 210 billion.